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Summary 
A monomorphic monoclonal antibody (LA45 antibody) reactive with "a new activation-induced 
surface structure on human T  lymphocytes" (LA45  antigen) that resembled free class I heavy 
chains has recently been described (Schnabl, E., H. Stockinger, O. Majdic, H. Gaugitsch, I.J.D. 
Lindley, D. Maurer,  A. Hajek-Rosenmayr, and W. Knapp. 1990. J. ExI~ Med. 171:1431). This 
antibody was used to done a class I-like heavy chain (LA45  gene) from the HUT 102 tumor 
cell, which paradoxically  did not give rise to the LA45 antigen on transfection into monkey 
COS cells. We show here that the LA45 gene is HLA-Aw66.2,  a previously uncharacterized 
allele of the HLA-A locus. The previously determined LA45 sequence differs from that of HLA- 
Aw66.2, from HUT 102, and the CR-B B cell line derived from the same individual as HUT 
102 by substitution of tryptophan for serine at position 4 in the oq domain. Transfection  of 
HLA-Aw66.2, and of a mutant of this gene with serine 4 substituted for tryptophan, into a 
human B cell line (C1R) both resulted in expression  of the LA45 epitope. Furthermore, we 
find expression of the LA45 epitope on Epstein Barr virus-transformed B cell lines as well as 
lectin-activated T cells, but not on long-term T  cell lines or unstimulated peripheral blood T 
cells. The specificity of the LA45 antibody is polymorphic and the presence of the LA45 epitope 
is precisely correlated with the sequence arginine, asparagine (RN) at residues 62 and 63 of the 
helix of the oll domain. The LA45 epitope is broadly distributed, being associated with half 
the alleles of both HLA-A and -B loci but none of the HLA-C locus. All the results are consistent 
with the presence of pools of flee HLA-A and -B heavy chains at the surfaces of certain cell 
types but not others Such molecules are probably responsible for the HLA-associated class I al- 
loantigens of lectin-activated T cells. We hypothesize the free heavy chains result from dissocia- 
tion of B2-microglobulin from subpopulations of empty HLA-A,B molecules, or molecules with 
weakly bound peptides, that vary in size depending on cellular activation and peptide supply. 
F 
'or >10 yr, it has been known that human T cells express 
novel HLA-encoded alloantigens, after  activation with 
PHA. These molecules are class I like in their polypeptide 
composition but are serologically distinct from the classical 
HLA-A, -B, and -C antigens (1-8).  Although it has been 
speculated that these determinants are human analogues of 
the mouse nonclassical Qa molecules, evaluation of such hy- 
potheses through molecular cloning of the genes encoding 
the human class I activation antigens has not been done (9). 
Recently, Schnabl et al. (10) described a mouse mAb, LA45, 
with an unusual specificity for class I HLA molecules, which 
may relate to the PHA-activated alloantigens.  This antibody, 
the result of immunization with the HTLV-l-infected tumor 
cell line HUT 102, was found to bind to PHA-activated pe- 
ripheral blood T cells and to T cells activated in vivo by in- 
fectious mononucleosis, but not to resting T cells. Immuno- 
precipitation and cocapping experiments showed that LA45 
bound to class I-like heavy chains at the cell surface not as- 
sociated with fl2-m. Furthermore, binding of the antibody 
to PHA-activated T cells from a panel of 12 individuals ap- 
peared independent of HLA type, suggesting "the LA45 an- 
tibody defines a monomorphic determinant on free class I 
heavy chains" (10). 
To identify genes encoding this unusual class I antigen, 
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pression library made from HUT 102 DNA. Clones derived 
from a single gene were obtained and these had a novel class 
I sequence. Transfection of this LA45 gene into monkey (COS) 
cells resulted in extensive intracellular expression,  but only 
slight expression of the LA45 antigen on the cell surface. These 
results suggested LA45 was not a conventional classical class 
I HLA antigen and that its gene may represent a previously 
uncharacterized nonclassical HLA class I locus. On the other 
hand, the observation that dass I heavy chains bound by LA45 
were electrophoretically similar to those of HLA-A,B mole- 
cules argued against this thesis.  In this paper,  we describe 
experiments that address this paradox, identify  the LA45 gene 
as HLA-Aw66.2, and provide further insight into the mole- 
cules and epitope recognized by the LA45 antibody. A rela- 
tionship between these molecules and the class I-like alloan- 
tigens of PHA-activated T  cells seems likely. 
Materials and Methods 
Preparation and Amplification of cDNA.  cDNA clones encoding 
HLA-Aw66 subtypes were from the EBV-transformed  B cell lines: 
MALS (HLA-Aw66.2, A3; Bw58), 25-1501 (HLA-Aw66.1, A2; 
B7, B35), CR-B (A30, Aw66.2; B17, B18), and HUT 102 (A30, 
Aw66.2; B17, B18). The boldface  alleles are those for which cDNA 
were cloned. These cell lines were kindly provided by Drs. F. M. 
Robbins and W. Bias (Johns Hopkins University), and N. M. Lardy 
and L. de Waal (University of Amsterdam). The construction of 
cDNA libraries, the isolation of  clones, and the sequencing of  M13 
subclones with synthetic oligonucleotide  primers were as described 
(11, 12). Sequence analyses were made with UWGCG software 
(13) and a VAX 11/789. Multiple clones were analyzed to obtain 
a consensus sequence for each allele. In particular, the first 200 bp 
from a combined total of  41 HLA-Aw66.1  and -Aw66.2 clones  were 
sequenced. All encoded serine at codon 4 of the eel domain, none 
having the tryptophan codon reported for the LA45 clone (10). 
PCR Mutagenesis and Transfection.  Mutagenesis  at nucleotide 
positions 83 and 84 of the coding region of HLA-Aw66.2 was per- 
formed using the PCR mutagenesis method described by Ho et 
al. (14). A 1.5-kb HindlII/SalI fragment of the mutated done was 
subcloned into M13. Mutagenesis was confirmed by sequencing 
the full-length cDNA. Wild-type mutant clones were inserted into 
plasmid vector PSRcxneo  (kindly provided by Dr. R. Tisch, Stan- 
ford University) by XbaI and HindlII digestion and ligation of 
gel-purified fragments. Transfection  into HLA-A,B-negative  CIR 
cells and flow cytometric analysis  were performed as described (15). 
Isoelectric Focusing.  This was performed according to the 10th 
International Workshop protocol (16, 17). 
Immunofluorescence.  To test for cell surface expression of HLA 
class I molecules and the LA45 epitope, CIR transfectants, EBV- 
transformed  cell  lines, PBL, PHA blasts, or T cell  lines  were washed, 
and aliquots of 2.5  x  10  s cells were then incubated for 30 min 
in 100/~1 PBS/1% BSA plus 20/zg/ml of one of the following 
antibodies: W6/32 (monomorphic anti-HLA class I); LA45 (anti- 
HLA class I heavy  chain); CVC.7 (an irrelevant  control of the same 
Ig-G2a isotype [anti-bovine clathrin light chain LC~]), or saline. 
The cells were washed twice and labeled with 100/~1 of 20/zg/ml 
affinity-purified  goat anti-mouse Ig-FITC (Tago Inc., Burlingame, 
CA) and incubated for 30 min on ice. Cells were washed in PBS, 
fixed for I min in 100/zl PBS/2% formalin, and diluted to 500 #1 
with PBS/1% BSA. Cells were then analyzed using a FACScan  | 
cytofluorograph (Becton Dickinson & Co., Mountain View, CA). 
PHA-activated cells were prepared from PBL by incubation in 
RPMI/10% FCS in the presence of PHA (1 ml of rehydrated  PHA 
[Gibco BILL]) added to 100 ml of cultured medium], with sup- 
plementation on day 3 with 50 U/ml Ib2, and harvesting for anal- 
ysis on day 5.  T  cell lines were the gift of Drs. P. K. Wesley, 
M. M. van Noesel, and A. M. Krensky (Stanford University). 
Results 
The LA45  cDNA  Clone Is Derived from  an HLA-Aw66 
Gene.  From comparisons with a limited number of class 
I genes, Schnabl et al. (10) found the LA45 gene to be "quite 
homologous to genes of the HLA class I gene family" and 
to bear characteristics  commonly associated with HLA-A al- 
leles (18). They did not, however, analyze the LA45 sequence 
with reference to the serological HLA type of the HUT 102 
cell from which the LA45 gene was derived (19). The HUT 
102 cell line was established  from the tumor cells of a Black 
male patient:  an EBV-transformed B cell line (CR-B) was 
also established  from his nonmalignant peripheral blood B 
cells (20). At that time, 1980, the HLA type of the patient 
was assessed to be HLA-A30, A31; B17, B18; DR2, DRw6, 
DQ1  using the available anti-HLA alloantisera. 
Comparison of the LA45 sequence with those for the sero- 
logically defined HLA-A,B types of HUT 102 showed no 
particular similarities  with HLA-A30, A31,  B17, or B18. 
We then compared the LA45 sequence to a data base of 27 
HLA-A, 33 HLA-B, 13 HLA-C alleles, and to eight sequences 
from nonclassical class I HLA genes. From pairwise compar- 
isons of complete sequences and the pattern of nucleotides 
at locus-specific  positions, LA45 is unequivocally an allele 
of the HLA-A locus and not of one of the nonclassical class 
I genes and pseudogenes that are related to HLA-A (Table 
1). In addition, the LA45 sequence was revealed to be a hy- 
brid of HLAoAw68.1 and HLA-A10 alleles, having a leader 
sequence  and oll domain similar to HLA-Aw68.1, and the 
remaining domains similar to the HLA-A10 subtypes HLA- 
A25  and -A26  (Fig.  1). 
This analysis strongly suggested the LA45 gene represented 
a previously unsequenced HLA-A allele expressed by the HUT 
102 cell line, but one that did not correspond to either of 
the serologically assigned HLA-A antigens. This was not im- 
Table  1.  Nucleotide  Differences between LA45 and Classical 
and Nonclassical HLA Alleles 
Nonclassical 
HLA-A  HLA-B  HLA-C  HLA-E, F, G, and H 
LA45  10-59"  82-120  95-119  84-159 
Intralocus comparison: AvA, BvB, CvC  1-62 
Interlocus comparison: AvB , BvC, CvA  57-132 
* Values given  are the range of nucleotide  differences  in pairwise com- 
parison of complete coding sequences. 
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B57  ..........  am  ..............................  p--a  ...............  g ....  m--sa--y-en-rialr  ....... 
Bw58  ..........  am  ..............................  p-t  ................  g ....  m--sa--y-en-rialr  ....... 
BI8  ........  h ..............  s .....  g  ............  p-t  .................  n-qis-tnt--y-es-rn  .......... 
A30  ........  f .......  s ......................................  r .....  q  .......  q .................... 
A25  ..............................................................  n ............  es-rialr  ......  d 
A26  ..-  ...........................................................  n ............  an  ............  d 
A66.2  ..............................................................  n ......  q .................... 
A66.1  ..............................................................  n ......  q ...................  d 
La45  ---w  ..........................................................  n ......  q  .................... 
A68.1  ..............................................................  n ......  q  .................... 
Consensus  GSHSMRYFYTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDRETRNVKAHSQTDRVDLGTLRGYYNQSEA 
Alpha 2 Domain 
91  120  150  182 
B57  ---i--v  .......  p---l---hd-s  ..............  s ......  t .....  q ......  r ...........  1 ..................  a 
Bw58  ---i  ........  l-p---l---hd-s  ..............  s ......  t .....  q ......  r ...........  1 ..................  a 
BIB  ....  1 .........  p---l---hd-s  ..............  s ......  t .....  q ......  r ...................  h ..........  a 
A30  ......  i ................  e-h  ...........................  q  ......  rw  .............................. 
A25  ..............  p ......................................  q  ....  t--e---w  ......  r ................... 
A26  ..............  p  ......................................  q ....  t--e---w  ......  r ................... 
A66.2  ..............  p  ......................................  q ....  t--e---w  ......  e ................... 
A66.1  ..............  p  ......................................  q ....  t--e---w  ......  r ................... 
La45  ..............  p  ......................................  q ....  t--e---w  ......  e ................... 
A68.1  ......  m  ................  r ............  k ..............  t--h  ..........  w .......................... 
Consensus  GSHTIQRMYGCDVGSDGRFLRGYQQDAYDGKDYIALNEDLRSWTAADMAAQITKRKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRT 
Alpha 3 Domain 
183  210  240  274 
B57  -p  ....  v---pi  ............  g ...............................  r .............  e  ..................... 
Bw58  -p  ....  v---p  .............  g ...............................  r .............  e  ..................... 
BI8  ........  p  v  px" .............................................................................  g  r  e 
A30  .........  p  pl" ..............................................................................  g  e 
A25  ...............................................................  s ............................ 
A26  ...............................................................  s ............................ 
A66.2  ...............................................................  s ............................ 
~66.1  ...............................................................  s ............................ 
La45  ...............................................................  s ............................ 
A68.1  ..............................................................  v ............................. 
Consensus  DAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRW 
Transmambrane Domain 
275  314 
B57  .....  s-v  .....  v---avlav-vi  ........  c ..... 
Bw58  .....  s .......  v---avlav-vi  .....  t--c  ..... 
BIB  .....  s .......  v---avlav-vi  .....  t--c  ..... 
A30  -I  .................  1 ................... 
~25  ........................  a .............. 
A26  ........................  a .............. 
A66.2  ........................  a .............. 
A66.1  ........................  a .............. 
La45  ........................  a .............. 
A68.1  ....................................... 
Consensus  EPSSQPTIPIVGIIAGLVLFGAVITGAVVAAVMWRRKSS 
C~toplasmic Domains 
315  342 
B57  gg  .........  c .............  *... 
Bw58  gg  .......................  *... 
BI8  gg  .......................  *.,. 
A30  .......  t ....................  * 
A25  ....................  m  .......  * 
A26  ....................  m  .......  * 
A56.2  ....................  m  .......  * 
AE6.1  ....................  m  .......  * 
5a45  ....................  m  .......  * 
A68.1  ............................  * 
Consensus  DRKGGSYSQAASSDSAQGSDVSLTACKV* 
Figure  1.  Amino add sequence comparisons  of LA45 with other  HLA-A and -B molecules.  The consensus  is derived from 31 HLA-A sequences. 
The dots indicate incompleted sequences; dashes indicate identities  with a consensus  sequence. Asterisks indicate a termination  codon. Sequences were 
obtained  from the following sources:  HLA-A68.1  (27);  LA45  (10); -A26  (43);  -A25,  -B57  (12); -A30 (44);  -B18  (18); -Bw58  (45). 
plausible as various factors could have contributed to impre- 
cision in the typing.  These include poor definition of HLA 
alleles of African origin,  the well-established crossreactivity 
of the HLA-A30 and HLA-A31 antigens, and difficulties as- 
sociated with typing lymphocytes from cancer patients. Given 
this hypothesis, the question then became whether the LA45 
allele corresponded to a defined serological antigen  or one 
that was totally  uncharacterized. 
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sideration of the unique structure of LA45 as an Aw68-A10 
hybrid and postulation that it would have antigenic proper- 
ties in common with one or both of these groups of antigens. 
For two reasons, alloantigenic  similarities with HLA-A10 were 
considered more likely: first, because sequences for all known 
serological  subtypes of HLA-Aw68 were  known  (21)  and 
shown to be distinct from LA45, whereas various antigens, 
including  HLA-Aw34, Aw43,  and Aw66 of the HLA-A10 
group,  had yet to be characterized in molecular detail;  and 
second, HLA-Aw68 is a relatively weak alloantigen compared 
to HLA-A10, indicating that the HLA-A10-like aspect of the 
LA45 structure would be likely to dominate.  We therefore 
predicted that LA45 would correspond to one of the more 
recently characterized antigens of the HLA-A10 group (22). 
Preliminary sequence analysis of HLA-A alleles from sero- 
logically well-characterized  B cell lines and isoelectric focusing 
of their expressed HLA-A,B proteins  revealed  HLA-Aw66, 
originally described by Mesman et al.  (23),  to be the most 
likely candidate for LA45.  The isoelectric focusing analysis 
also revealed heterogeneity in molecules typed as HLA-Aw66 
(Fig.  2). The Aw66 molecules of the 25-1501  cell of Cauca- 
sian  origin  was different from that  of the MALS cell line, 
which came from an American Black individual.  Complete 
nucleotide sequence determination of Aw66 alleles from these 
two cell lines showed the two sequences were highly related, 
both to each other and to that  of the LA45 clone (Fig.  3). 
The HLA-Aw66.1 subtype from cell line 25-1501 is a perfect 
hybrid of A68.1 and either A25 or A26, and is likely to have 
arisen  by  recombination  between  these  alleles.  Flanking 
markers limit such putative recombination to within codons 
77-89  of exon 2.  The  HLA-Aw66.2 subtype from MALS 
Figure 2.  Isoelectric  focusing pattern of HLA-Aw66 molecules from 
the 25-1501 (lane I), CR-B (lane 2), and MALS (lane 3) cell lines. Im- 
munoprecipitates were with the W6/32 mAb after depletion of HLA-B 
and -C molecules  with the 4E antibody. Depletion  of HLA-B  was incom- 
plete for lanes 1 and 3. Two subtypes  of HLA-Aw66  (Aw66.1  and Aw66.2) 
are resolved.  The CR-B B cell  line is from the same  individual as the HUT 
102 tumor cell line. 
differs from Aw66.1 by four nucleotide substitutions resulting 
in amino acid substitutions of D-~A at position 90 and R--~E 
at position 163.  It is HLA-Aw66.2 that is most like LA45, 
differences being seen at just three nucleotide positions. First 
is a single nucleotide deletion  in exon  1 of LA45.  This  is 
almost certainly the result of a sequencing error,  as Schnabl 
et al. (10) showed the LA45 clone directs synthesis of an an- 
tigenically recognizable class I heavy chain of normal length, 
which would not occur with  the change in reading frame 
created by this deletion. The other two are adjacent substitu- 
tions in codon 4 of exon 2 and lead to substitution of trypto- 
phan for serine at position 4 of the oll domain.  This substi- 
tution is highly unusual as serine 4 is conserved in all other 
HLA-A, -B, and -C sequences. Three alternative origins for 
these latter two differences were considered: first, that LA45 
represents a third subtype of HLA-Aw66 found in the human 
population,  second,  that  LA45  represents  a mutant  HLA- 
Aw66.2 allele that arose during either the in vivo or in vitro 
growth of the tumor cells, and third, that the differences be- 
tween LA45  and  the  HLA-Aw66.  sequences represent  ex- 
perimental  artifacts. 
To distinguish these possibilities, we analyzed the HLA-A 
alleles expressed in HUT 102 (the source of the LA45 cDNA 
clones) and in the B cell line (CR-B) derived from the same 
individual. If the LA45 sequence is that of a third HLA-Aw66 
subtype, then the LA45 sequence should be obtained from 
both HUT  102 and CR-B, whereas if the differences were 
due to somatic mutation in the tumor cells, then they should 
be seen in HUT 102 but not the B cell line.  Clones corre- 
sponding to two distinctive HLA-A alleles were isolated from 
both cell lines.  No differences in the sequences of clones de- 
rived from the B cell line and the tumor cell line were found. 
One allele was identical to the HLA-Aw66.2 isolated from 
the MALS cell line,  and the second allele  was a subtype of 
HLA-A30. Finding identical HLAoAw66.2 genes in the HUT 
102, CR-B, and MALS cell lines argues against the the first 
two possibilities and therefore indicates that  the differences 
between the LA45 and HLA-Aw66.2 sequences are either due 
to mutations  specific to the subline of HUT 102 cells used 
by Schnabl et al. (10), to mutations introduced during cloning 
procedures, or to sequencing errors. Of interest is that both 
HLA-A alleles of HUT 102 have "new" sequences, representing 
alleles that have not been clearly defined by serology and are 
possibly subtypes that are preft'tentially  found in African Blacks 
and their descendants. This probably explains the discrepancy 
between the "molecular typing" reported here and the original 
serological typing.  For example,  the HLA-A30 subtype of 
HUT 102 is not common and may well have given reactions 
with alloantisera directed against HLA-A30 and -A31. Reas- 
sessment  of the  serological  typing  of the  HUT  102  and 
CP,-B cell lines showed reactivities with alloantisera  defining 
HLA-Aw66. 
The Unique Substitution at Position 4 in the LA 4  5 Heavy Chain 
Does Not Affect Cell Surface  Expression or Detection of  the LA 45 
Epitop~  The single difference between the class I heavy chain 
encoded by the HLA-Aw66.2 and LA45 sequences is the sub- 
stitution of serine for tryptophan at position 4. To examine 
the effect of this difference upon cell surface expression, we 
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ATGGCCGTCATGGCGCCCCGAACCCTCGTCCTGCTACTCTCGGGGGCCCTGGCCCTGACCCAGACCTGGGCGG 
1  30  60  i00 
............................  c ....................................................................... 
.........  gg .................  c ....................................................................... 
............................  C ....................................................................... 
............................  c ....................................................................... 
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GCTCCCACTCCATGAGGTATTTCTACACATCCGTGTCCCGGCCCGGCCGCGGGGAGCCCCGCTTCATCGCCGTGGGCTACGTGGACGACACGCAGTTCGT 
i01  130  160  200 
.....................................................................................  a-c  ............ 
.....................................................................................  a-c  ............ 
.....................................................................................  a-c  ............ 
.....................................................................................  a-c  ............ 
.....................................................................................  a-c  ............ 
GCGGTTCGACAGCGACGCCGCGAGCCAGAGGATGGAG•CGCGGGCGCCGTGGATAGAGCAGGAGGGGCCGGAGTATTGGGACCGGGAGACACGGAATGTG 
201  230  270 
........  g ............................................................. 
........  g .............................................................. 
........  g ............................................................. 
........  g ..........................................................  a-- 
.........................  c-a  .......................................  a-- 
AAGGCCCACTCACAGACTGACCGAGTGGACCTGGGGACCCTGCGCGGCTACTACAACCAGAGCGAGGCCG 
1  30  60  i00 
..................  t ..................................................  g .............................. 
.........................................  c .....................................  t .................... 
.........................................  c .....................................  t .................... 
.........................................  c .....................................  t .................... 
.........................................  c .....................................  t .................... 
GTTCTCACACCATCCAGAGGATGTATGGCTGCGACGTGGGGTCGGACGGGCGCTTCCTCCGCGGGTACCAGCAGGACG•CTACGACGGCAAGGATTACAT 
101  130  160  200 
.........  a ...................................  a .......  c ........  a ................................  g .... 
..........................................................  c ..............  a .........  a ...........  g .... 
..........................................................  c  ..............  a  .........  a  ...........  g  .... 
..........................................................  c ..............  a .........  a ...........  g .... 
....................................  c .....................  c ..............  a .........  a ...........  g .... 
CG•CCTGAACGAGGA•CTG•G•TCTTGGAC•G•GGCGGA•ATGGCGG•TCAGATCAcCAAGCGCAAGTGGGAGGCGGCcCATGTGGCGGAGCAGTTGAGA 
201  230  276 
............................................................................ 
...............  ga ........................................................... 
...............  ga  ........................................................... 
...............  cg ........................................................... 
...............  cg ........................................................... 
GCCTACCTGGAGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGGAGAACGGGAAGGAGACGCTGCAGCGCACGG 
1  30  60  i00 
..........  a ...................................  a ..................................................... 
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ACGCCCCCAAGACGCATATGACTCACCACGCTGTCTCTGACCATGAGGCCACCCTGAGGTGCTGGGCCCTGAGCTTCTACCCTGCGGAGATCACACTGAC 
101  130  160  200 
......................................................................................  t ............. 
........................................................................................  t ........... 
........................................................................................  t ........... 
.....................................................................  g ..................  t ........... 
...............  - .....................................................  g ..................  t ........... 
CTGGCAGCGGGATGGGGAGGA•CAGACCCAGGACACGGAGCTCGTGGAGACCAGGCCTGCAGGGGATGGAACCTTC•AGAAGTGGGCGGCTGTGGTGGTG 
201  230  276 
................................................  t ........................... 
............................................................................ 
............................................................................ 
............................................................................ 
............................................................................ 
CCTTCTGGACAGGAGCAGAGATACACCTGCCATGTGCAGCATGAGGGTCTGCCCAAGCCCCTCACCCTGAGATGGG 
1  30  60  100 
.................................................................................................... 
.......................................................................  g ............................ 
.......................................................................  g ............................ 
.......................................................................  g ............................ 
.......................................................................  g ............................ 
AGCCGTCTTCCCAGCC•ACCATCCCCATCGTGGG•ATCATTGCTGGCCTGGTTCTCTTTGGAGCTGTGATCACTGGAGCTGTGGTCGCTGCTGTGATGTG 
i01  117 
GAGGAGGAAGAGCTCAG 
1  30  60  86 
...................................................................................... 
.....................................................................................  a 
.....................................................................................  a 
.....................................................................................  a 
.....................................................................................  a 
ATAGAAAAGGAGGGAGCTACTCTCAGGCTGCAAGCAGTGACAGTGCCCAGGGCTCTGATGTGTCTCTCACAGCTTGTAAAGTGTGA 
Figure 3.  Nucleotide sequence comparison of LA45, A68.1, A26, and the Aw66.1 and Aw66.2 subtypes. Allelic sequences are compared to the 
consensus derived from 31 HLA-A  sequences, and identity is denoted by a dash. The LA45 and HLA-A68.1  sequences were from references 10 and 
27,  respectively. The Aw66.1 and Aw66.2 sequence data have been submitted  to the EMBL/GenBank  Data Libraries under the accession numbers 
X61711  and X61712,  respectively. 
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Figure 4.  Analysis  of the cell 
surface expression of LA45 and 
W6/32 epitopes by untransfected 
C1R cells (a) and by C1R cells 
transfected  with  LA45 (b)  or 
HLA-Aw66.2 (c) cDNA clones. 
The plots are immunofluorescence 
of FITC goat anti-mouse  Ig as 
analyzed  by flow cytometry.  Bind- 
ing of W6/32 is given  by the solid 
line, of LA45 by the dotted line, 
and of the negative control anti- 
body by the dashed line. 
made a mutant of HLA-Aw66.2 with tryptophan at position 
4.  Mutant  and wild-type genes were subcloned  into  the 
PSRotNeo expression  vector and electroporated  into the human 
HLA-A,B-negative cell line C1R. After 2 wk of drug selec- 
Table  2.  Expression of LA45 and W6/32 Epitopes by C1R Cells 
and by EBV-transformed B Cells Lines 
tion and culture,  considerable and comparable increases in 
the amount of B~-m-assodated class I  heavy chains were 
found at the surface of cells transfected with both the wild- 
type and mutant genes (Fig. 4). These complexes were de- 
tected with the antibody W6/32, which is dependent upon 
the association of class I heavy chain and ~2-m (24). High 
expressing cells were selected using the FACScan  |  and the 
mutant HLA-Aw66.2 gene was reisolated and sequenced to 
confirm the mutation. Thus, the apparent difference  between 
LA45 and HLA-Aw66.2 has no gross effect  upon the assembly, 
transport,  and stability of the class I heavy chain. 
Furthermore, C1R cells transfected with wild-type or mu- 
tant HLA-Aw66.2 genes bound the LA45 mAb, whereas un- 
transfected CIR cells did not. This experiment provides a 
direct demonstration that the LA45 antigen is the product 
of a classical HLA-A gene and that no qualitative difference 
in its expression is caused by the substitution at position  4 
that distinguishes LA45 from HLA-Aw66.2. As the C1R mu- 
tant is derived from an EBV-transformed cell, a further im- 
portant conclusion  from this analysis is that expression of 
the LA45 antigen is not restricted to activated T cells. The 
failure of the LA45 epitope to be expressed when the LA45 
gene was transfected into COS cells (10) is therefore likely 
to have been a function of the recipient cell rather than of 
the LA45 clone. 
Transfected with Single HLA-A or -B Genes 
mAb 
Cell  HLA type  W6/32  CVC-7  LA45  No mAb 
Aw68/CIR  Aw68  911  5.4  169,3  3.2 
Aw69/CIIL  Aw69  394  5.2  188,6  2.7 
A2/C1R  A2  1,062  3.9  14.7  2.1 
B27/C1R  B27  1,743  3.9  7.0  1.9 
B7/CIR  B7  1,697  3.3  153.0  2.1 
Aw66.2/C1R  Aw66.2  312  3.8  19.3  2.7 
LA45/C1R  LA45  581  4.7  74.6  4.1 
GRC138  A2; B40,62  2,068  4.2  8.2  5.4 
JESTHOM  A2; B27  1,775  4.2  7.5  1.9 
JY  A2; B7  2,050  6.8  160.0  3.3 
DEM  A2; B57  2,125  4.5  10.7  2.4 
SPOOl0  A2;  B44  2,013  2.8  16.0  2.2 
BM16  A2; B18  1,295  3.6  145.3  2.6 
HOM2  A3; B27  1,072  3.5  19.8  2.4 
OLGA  A31;  B62  1,857  3.4  11.5  2.6 
DAUDI  -  4.4  3.5  3.2  2.4 
C1R  -  111.9  7.0  6.8  3.0 
Cells were labeled  using W6/32 (monomorphic anti-HLA class  I), CVC.7 (irrelevant  control, LA45, or saline  as the first step, and FITC goat anti-mouse 
Ig as the second step. They were then analyzed using a FACScan  |  cytofluorograph. Numbers represent the mean channel fluorescence  for each anti- 
body. The bottom two lines show the staining of the HLA-A,B,C-negative DAUDI cell line and the HLA-A,B-negative C1R transfectant recipient 
cell line. 
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B Cells and Is Determined by Residues 62 and 63 of the oil Helix 
of HLA-A and -B Heavy Chains.  To determine if the results 
obtained with class I transfectants of the C1R mutant extend 
to normal EBV-transformed B cell lines, we compared binding 
of the LA45 antibody to panels of each type of cell. Among 
both sets of  cells there were some that were positive for LA45 
binding and others that were negative, demonstrating poly- 
morphism in the distribution of the antibody epitope. From 
analysis of the transfectants it was clear that LA45-positive 
and -negative molecules derived from both the HLA-A and 
HLA-B loci:  HLA-Aw68,  -Aw69,  and -B7  were positive, 
whereas HLA-A2 and -B27 were negative (Table 2).  Com- 
parison of HLA types and reaction patterns of the EBV lines 
and transfectants reveals that HLA-A3 is negative and HLA- 
B18 is positive for the LA45 epitope. 
Inspection of the amino acid sequences of the LA45-positive 
and -negative class I heavy chains shows that substitutions 
at positions 62 and 63 are the only ones to correlate with 
the distribution of the LA45 epitope.  These residues  are at 
the NH2-terminal end of the helix of the or1 domain, and 
both contribute to the antigen recognition site: LA45-positive 
molecules have arginine at position 62 and asparagine  at po- 
sition 63,  whereas LA45-negative molecules have a variety 
of other sequence  motifs. This analysis suggested that the 
LA45 epitope is critically dependent upon arginine 62 and 
asparagine 63. One possibility is that the antibody directly 
contacts these residues, and another is that they have confor- 
mational effects on distant residues that form the actual epi- 
tope. If the latter were true, then one might expect denatu- 
ration to change the polymorphic specificity  of the LA45 
antibody. This was not the case, as shown by Western blot 
analysis of cell lysates made from the panel of CIR transfec- 
tants. Heavy chains from HLA-Aw66.2, -Aw68.1, -Aw69, and 
-B7 transfectants reacted with the LA45 antibody, whereas 
those from HLA-A2 and -B27 did not. All heavy chains ex- 
cept HLA-A2 reacted with the HC10 mAb (25), which has 
a distinctive specificity for free, denatured class I HLA heavy 
chains (data not shown). Our results therefore support a model 
in which LA45 is a linear epitope centered on arginine 62 
and asparagine  63. 
This allows HLA-A,B,C molecules to be divided into groups 
predicted to be positive and negative for the LA45 epitope. 
All HLA-C alleles are predicted to be negative, whereas HLA-A 
and -B molecules fairly evenly distribute between the two 
Table  4.  Expression of LA45 and W6/32 Epitopes on Resting 
and Activated L ymphocytes 
Cells 
mAb 
HLA type  W6/32  CVC-7  LA45 No mAb 
AML-PBL  A1,2; B44,8  565  1.6  3.7  1.5 
AML-PHA  1,537  1.8  24.4  1.5 
CL-PBL  A2,24;  B44,62  472  1.3  2.1  1.3 
CL-PHA  1,111  1.4  2.3  1.5 
AMF-PBL  A3,w68; B65  555  1.3  3.9  1.2 
AMF-PHA  1,367  1.2  55.4  1.2 
AMK-PBL  A3; B7  464  2.2  8.0  1.7 
AMK-PHA  1,482  2.6  41.5  2.2 
AMK-EBV  2,263  3.2  81.6  3.2 
AMK-AJY  1,121  2.2  4.4  1.3 
HUT78  A1; B62  2,031  5.3  7.8  5.6 
HSB  A1,2; B12,44  1,637  3.2  4.2  3.2 
BG  A3,23; B50,55  1,227  2.0  13.3  2.1 
JURKAT  A3; B35  690  2.0  3.7  2.0 
B27/C1R  B27  2,068  1.9  13.3  1.7 
B7/C1R  B7  1,537  2.1  173.9  2.2 
A2/C1R  A2  903  2.0  17.9  1.9 
C1R  -  156  4.1  11.0  3.9 
PBL and day 5 PHA blasts were from four donors (AML, CL, AMF, 
and AMK). In addition, an EBV-transformed  B cell line (AMK-EBV) 
and a long-term  alloreactive  CTL line with specificity  for HLA-A2  (AMK- 
JY) derived from the PBL of donor AMK were also tested. HUT 78, 
HSB, BG, and Jurkat are T tumor cell lines. Cells were labeled with 
W6/32 (monomorphic  anti-HLA  class I), CVC.7 (irrelevant control), 
LA45 antibody, or saline as the first step, and FITC goat anti-mouse 
Ig as the second step. They were then analyzed using a FACScan  | 
cytofluorograph.  Numbers represent the mean channel fluorescence  for 
each antibody. 
groups (Table 3). To test these predictions, we analyzed the 
distribution of the LA45 epitope on resting and PHA-activated 
T  cells from four HLA type donors (Table 4).  Confirming 
the results of Schnabl  et al.  (10), we found no binding of 
Table  3.  Prec~ted Polymorphic Specificity of the LA45 Antibody 
Predicted to be LA45-positive R62,  N63-containing  Predicted to be LA45 negative 
A25, A26, Aw33,  Aw66,  Aw68, Aw69 
B7, B8, B14, B18, B35, B38, B39, Bw42, B51, 
Bw53, Bw65, Bw78 
A1, A2, A3, All, A23, A24, A29, A30, A31, A32 
B13, B27, B37, B40*, Bw41, B44, Bw46, B47, B49, 
B52, Bw57, Bw58, Bw60, Bw62 
All HLA-C 
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from three of the donors became positive, while the fourth 
remained negative. This last donor, CL, expresses HLA-A2, 
24; -B44, 62, which are all molecules predicted to be LA45 
negative. In contrast, the other three donors all have at least 
one HLA-A, or -B molecule predicted to be LA45 positive. 
Given the striking difference in binding of LA45 to resting 
and PHA-activated peripheral T cells, we were interested to 
assess other types of human T cells for the presence of this 
epitope. Five T cell-derived cell lines were examined and none 
expressed the LA45 epitope (Table 4). For HUT78 and HSB, 
this is simply explained by the fact that neither cell types 
for HLA-A, -B, and -C molecules predicted to be LA45 posi- 
tive. Jurkat and two recently stimulated alloreactive cytotoxic 
T cell lines, however, all express HLA-B molecules predicted 
to be LA45 positive. In the case of donor AMK, we know 
the prediction to be true, as PHA-activated T cells and an 
EBV-transformed B cell line from the same individual were 
both LA45 positive.  The absence of the LA45 epitope  on 
the AMK alloreactive CTL is not simply correlated with it 
being of CD8 phenotype, as many of the LA45 positive cells 
in the culture of PHA-activated T cells are of this type. Rather, 
it seems that the LA45 epitope is differentially expressed in 
T cells at various activation states. Clearly, the LA45 epitope 
is not found on all types of activated T  cells. 
Discussion 
Nature of the LA45 Gene.  We have shown that the novel 
class I HLA gene, LA45,  isolated from HUT 102 cells by 
Schnabl et al. (10), corresponds to a subtype of HLA-Aw66, 
a recently defined antigen of the HLA-A locus. This antigen 
is difficult to distinguish  by HLA serology  (serologists in 
North America and Europe do not agree on its definition 
[26]), and knowledge of its sequence, its characteristic hy- 
brid structure, and the existence of two subtypes should im- 
prove this situation. We isolated and sequenced identical HLA- 
Aw66.2  alldes  from the HUT 102 T  cell tumor line, the 
CR-B B cell line derived from the same individual as HUT 
102, and the B cell line MALS derived from an unrelated 
individual. We also sequenced the HLA-Aw66.1 subtype from 
the 25-1501 B cell line. In none of the 41 HLA-Aw66.2 clones 
analyzed have we seen the two unusual nucleotide substitu- 
tions in codon 4 of the LA45 sequence, leading to the con- 
clusion that these differences are either unique to the subline 
of HUT 102 used by Schnabl et al. (10), misincorporations 
produced during cDNA cloning, or sequencing artifacts. It 
is unlikely there has been any mix-up of cell lines due to the 
rarity of the HLA-Aw66 antigen. Either way, these substitu- 
tions are unlikely to be found in HLA-Aw66 alldes in the 
human population. 
HLA-Aw66.1 is the third example of a class I HLA allele 
that is a simple recombinant of two other alleles, the other 
examples being HLA-Aw69 formed from A2.1 and Aw68.1 
(27) and HLA-Bw42 formed from B7 and B8 (28). In each 
case, the recombination is such that the two halves of the 
antigen recognition site derive from different alleles, and this 
may be a particularly  effective way for the creation of new 
antigen-presenting functions from existing  alleles. 
Specificity of the LAg5Antibody.  In contrast to the earlier 
conclusion that the LA45 mAb has monomorphic specificity 
(10), we clearly demonstrate that its specificity  is polymorphic. 
Moreover, LA45 reactions are precisely correlated with the 
presence of both arginine at position 62 and asparagine at 
position 63 in the at helix,  indicating these residues form 
a critical part of the LA45 epitope. Roughly half of the al- 
Ides at the HLA-A and -B loci are predicted to be positive 
for the LA45 epitope, and the high probability with which 
any individual  will have at least one LA45-positive HLA- 
A,B molecule probably explains why Schnabl et al. (10) found 
that PHA-activated T cells from all 12 of the individuals they 
analyzed were positive for the LA45 epitope.  Of the three 
T cell samples from patients with infectious mononucleosis, 
one was negative for LA45 binding, which could now be 
interpreted in terms of the polymorphic specificity of the an- 
tibody. Their observation, in an isodectric focusing experi- 
ment, that LA45 precipitates had the same binding patterns 
as precipitates with the monomorphic anti-class I antibody 
W6/32 (10) would be consistent with all HLA-A and -B mol- 
ecules of the cells tested being LA45 positive. In such experi- 
ments, the lower levels of HLA-C are rarely visualized. The 
HUT 102 tumor cell line that was the immunogen for gener- 
ating the LA45 antibody expresses HLA-Aw66.2 and -B18 
molecules that are positive for the LA45 epitope, and HLA- 
A30 and -B17 molecules that are negative. 
The second issue regarding the specificity of the LA45 an- 
tibody is its tissue distribution. On the basis of reactions with 
lectin-activated T cells and in vivo activated T calls from in- 
fectious mononucleosis patients,  LA45 was described as "a 
new activation-induced structure on human T lymphocytes" 
(10). First, we have confirmed the specificity  for PHA-activated 
PBL and the absence of reactivity with unstimulated PBL, 
second, we show that human T cells activated by other means 
need not necessarily express LA45 determinants, and third, 
that  the  LA45  epitope  is  ubiquitously  found  on  EBb;- 
transformed  B cell lines providing they express an appropriate 
"LA45-positive"  HLA-A or -B allele. 
Origin of  LA 4  5-reactive Free  HLA-A,B Heavy Chains on Cell 
Surfaces.  Our results and those of Schnabl et al. (10) are en- 
tirely consistent with the LA45 antibody having specificity 
for free R62/N63-containing HLA-A,B heavy chains, both 
in solution and at the cell surface. For human cells, it has 
consistently been reported (29, 30) that class I HLA-A,B heavy 
chains are only transported to the cell surface when associated 
with fl2-m, though one mouse class I molecule, H-2D  b, has 
been shown to reach the plasma membrane in the absence 
of/~2-m (31). Thus, the free HLA-A,B heavy chains at the 
surface of EBV-transformed B cells and PHA-activated T cells 
are likely to have originated from complexes of heavy chain 
and/~2-m from which the/$2-m has dissociated. The popu- 
lation of such molecules on resting T  cells is undetectable 
but increases to 25,000-60,000  molecules per cell on PHA 
activation (10). This difference is not associated with gross 
changes in the level of class I HLA, which increases two- 
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PBL (32). Hansen and colleagues (33) have reported a similar 
phenomenon for the mouse H-2L  d molecule in which free 
heavy chains with altered conformation and protease suscep- 
tibility were found on all cell types they examined. 
One explanation for the occurrence of free HLA-A,B heavy 
chains on cell surfaces is they represent intermediates in the 
general pathway of degradation of class I molecules. This 
scheme, however, cannot explain the difference  between resting 
and activated T cells without postulating different degrada- 
tive pathways in the two cell types. A second explanation, 
and one we favor, is that LA45 reactivity is the property of 
a subpopulation of HLA-A and -B molecules produced in 
PHA-activated T  and EBV-transformed  B cells but not in 
resting cells. 
A possible mechanism is for LA45-reactive  heavy chains, 
which from the estimates of McCune et al. (32) and Schnabl 
et al. (10) may comprise 10-20% of the total heavy chains, 
to be derived from empty molecules, that is complexes of 
heavy chain and fl2-m that arrive at the cell surface without 
a bound peptide. Empty molecules have been detected on the 
surfaces of mutant and normal cells (33-36), and we recently 
provided evidence for their presence on the surface of EBV- 
transformed B cell lines (37). A characteristic  of empty class 
I molecules at the cell surface is they more rapidly dissociate 
from  fl2-m  than  molecules  with  bound  peptide.  Thus, 
empty HLAoA,B molecules at the cell surface would be ex- 
pected to give rise to a pool of free and potentially LA45- 
reactive heavy chains. Alternatively, the free heavy chains may 
derive from HLA-A,B molecules that arrive at the cell sur- 
face with weakly bound peptides. Such molecules are likely 
to be less stable than those with strongly bound peptides and 
could,  by  dissociation of both  peptides  and  flz-m,  be  a 
source of free heavy chains. 
From recent investigations, it appears that an abundance 
of suitable binding peptides is not always available to class 
I molecules (33-37).  Increased synthesis of class I heavy chains 
and fl2-m in activated T  cells may therefore not be accom- 
panied by an equivalent increase in available peptides in the 
endoplasmic reticulum, thereby leading to greater numbers 
of empty molecules and molecules with less tightly bound 
peptides. In this manner, quantitative changes in the amounts 
of peptides and heavy chains can lead to qualitative differ- 
ences in the HLA-A,B molecules formed. This model can 
explain the observation that monkey (COS) cells transfected 
with the LA45 cDNA failed to express the LA45 epitope, 
although plenty of LA45-reactive free heavy chains were found 
within the cell (10). If peptide supply in COS cells is not 
limiting, then all LA45 heavy chains will be incorporated 
into molecules with tightly bound peptide. In this case, free 
heavy chains will not be produced at the cell surface in de- 
tectable amounts and the phenotype of the transfected cells 
will be like that of resting PBL, i.e., LA45 negative.  That 
the result of transfection is indeed a function of the recipient 
cell is indicated by our finding that transfection ofLA45 cDNA 
into an EBV-transformed B cell line gave cell surface expres- 
sion of the LA45 epitope. 
Relationship  to  HLA  Alloantigens  on  Activated  T  Cells. 
Multiple reports of HLA-linked alloantigens found on acti- 
vated T  but not resting T  calls have been described (1-8). 
The presence of these alloantigens on EBV-transformed B cells 
is not known and probably di~cult to examine due to the 
many B cell antibodies in human alloantisera. These antigens 
have usually been correlated with haplotypes encoding par- 
ticular HLA-A alldes and may, like the LA45 antigen, repre- 
sent antigenic determinants formed by distinctive conforma- 
tions of the HLA heavy chain. Recently, Crepaldi et al. (38, 
39) have in fact shown, in the case of activation alloantigens 
correlating with HLA-A1- and HLA-A2-containing haplo- 
types, that the alloantisera precipitate class I heavy chains that 
by isoelectric focusing patterns are identical to HLA-A1 and 
HLA-A2. Conformational distinction in the molecules con- 
taining these heavy chains was demonstrated by their lack 
of reactivity with the monomorphic anti-class I HLA anti- 
body W6/32 (39). In contrast to the LA45 determinant, the 
T cell alloantigens are the property of 132-m-assodated class 
I molecules as they are cocapped/blocked and precipitated 
with anti-fl~.-m. Given the similarities in cellular occurrence 
and HLA-A association of the LA45 and T cell aUoantigens, 
it is conceivable that both sets of antigenic determinants are 
manifestations of the same phenomenon. The apparent differ- 
ence in fl2-m association need not rule this out. For example, 
the target molecules of LA45 and the alloantibodies may come 
from the same set of empty and relatively labile fl2-m-asso- 
dated molecules: the alloantibodies binding them while they 
are still associated with fl2-m, LA45 binding the free heavy 
chains after dissociation of Bz-m. Also possible is that bind- 
ing of the LA45 mAb may actually induce dissociation of 
fl2-m from empty molecules. 
That aUoantigens of activated T cells are formed by class 
I molecules such as HLA-A2 and HLA-A24(6), which do not 
have the LA45 epitope, suggests formation of the conforma- 
tionally distinctive or empty form is not restricted to mole- 
cules with this particular epitope and sequence motif. Sup- 
porting this view is the recent finding of a free HLA-C heavy 
chain on the surface of virus-infected cells (40).  Thus, the 
phenomena described for LA45-reactive HLA-A,B molecules 
may be a more general property of the products of class I 
HLA alleles. Furthermore, there is no reason to believe their 
expression will be limited to cells of the lymphoid lineage, 
in which case the alloantigens of free dass I heavy chains may 
be a feature of other types of activated cells. 
During primary activation, human T cells are likely to un- 
dergo considerable changes in their patterns of antigen pre- 
sentation. Expression of class II HLA molecules is turned 
on (41) and that of class I is increased by a factor of two to 
three (32). If the activation pathways of protein degradation 
and peptide transport are not commensurately increased, then 
limited peptide supply may create an effective competition 
for endogenous peptides between class I and class II mole- 
cules. The presence of increased numbers of class I molecules 
on the surfaces of activated cells may facilitate the presenta- 
tion of peptides of exogenous origin by class I molecules (37). 
Finally, the degradation of proteolytically susceptible free dass 
1093  Madrigal et al. I heavy chains in the endocytic pathway may lead to increased 
presentation of dass I peptides by class II molecules (42). Such 
changes in antigen presentation could be involved in the ini- 
tiation of regulatory T cell responses. The lack of the LA45 
epitope on lines of human T cells that have undergone mul- 
tiple stimulations with antigen indicates that the changes 
leading to the expression of conformationaUy  distinct empty 
molecules on activated T cells are reversible. Thus, cell sur- 
face expression of antigenically distinct free HLA-A,B heavy 
chains may mark particular stages of human T cell differen- 
tiation. 
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